Adenovirus-mediated gene transfer of interferon gamma (AdIFN) elicits rejection of intracerebral Lewis lung carcinoma. In this system, gene transfer into brain parenchymal cells is both necessary and sufficient to generate the antitumor response. Despite persistent parenchymal inflammation and demyelination, wild-type mice injected intracerebrally with either AdIFN or ␤-galactosidase adenovirus (AdBGAL) perform as well as non-injected animals in behavioral, memory, and motor tests. Both AdIFN and
Introduction
Despite many aggressive multimodality conventional therapeutic protocols over the past two decades, the prognosis of patients diagnosed with primary and metastatic malignant brain tumors remains poor. 1, 2 In many cases, systemic malignancies also metastasize to the nervous system with a prevalence of about twice as common as primary neoplasms in adults. These facts highlight the need for novel molecular therapies for malignant brain cancer. Data from this laboratory showed that Fisher rats, implanted by syngeneic malignant glioma cells (RT2) genetically modified in vitro to secrete interferon gamma, survive longer than controls and reject the tumor. 3 Furthermore, treatment of mice harboring intracerebral Lewis lung carcinoma (3LL) with AdIFN elicits significant prolongation of survival times and tumor rejection. In the latter model, the antitumor effects of AdIFN are independent of adaptive cellular immune mechanisms and appear to be mediated by anti-angiogenesis. 4 AdIFN transduces not only 3LL cells but also brain parenchymal cells including endothelial cells, neurons, microglia, and astrocytes in vivo. Furthermore, transgene expression persists longer in the brain than in tumor, and transfer of interferon gamma into brain parenchymal cells rather than tumor cells is both necessary and sufficient to generate the antitumor therapeutic benefits. AdBGAL elicit demyelination whose incidence rises sharply when the lowest effective dose of AdIFN is exceeded. Therefore, transfer of interferon gamma into brain parenchyma does not seem to elicit detectable cognitive, behavioral or motor deficits. Furthermore, gene transfer into the brain, by adenoviral vectors currently in clinical trials, is associated with a narrow therapeutic window where the incidence of demyelination rises sharply soon after the effective dose is achieved. Gene Therapy (2000) 7, 2094-2098.
The use of first-and second-generation adenoviral vectors is hampered by inflammation due to an immune response generated against the viral-encoded proteins and the transduced cells. 6, 7 A recent report describes chronic inflammation, infiltration by CD4 and CD8 T lymphocytes, demyelination, and persistent transgene expression in the brains of rats that survive syngeneic glioma treated by adenovirus-mediated gene transfer of herpes simplex thymidine kinase followed by systemic ganciclovir. 8 The experiments in this article were designed to examine the cognitive and pathological effects, if any, of AdBGAL and AdIFN on normal mouse brain.
Results
To study the adverse effects of adenovirus-mediated gene transfer of interferon gamma and LacZ into normal brains, two groups of age-and sex-matched mice were injected intracerebrally with AdIFN and AdBGAL. The dose of adenovirus was chosen as the lowest of AdIFN capable of eliciting an antitumor response (10 l of 0.8 × 10 12 viral particles/ml; data not shown). Three to six months after injection, animals were tested for locomotion, and memory using a battery of murine behavioral tests and contrasted to a group of age-and sex-matched uninjected control mice. As compared with controls, mice that received AdBGAL or AdIFN intracerebrally did not exhibit detectable behavioral, motor or cognitive deficits. They performed as well as negative controls in behavioral tests for anxiety (open field and elevated plus maze, Figure 1 ), locomotion (elevated plus (Figure 2d ). However, pathological examination performed at 3 months (n = 5 each group) and 6 months (AdIFN, n = 10 and AdBGAL, n = 9) showed persistent inflammation as evidenced by astrocytosis and microglial infiltration at the site of injection ( Figure 3 ). Furthermore, two of five (40%) and none of five of the brains injected with AdBGAL and AdIFN showed demyelination at 3 months, respectively ( Figure  3c and f). In addition, four of nine (44%) and two of 10 (20%) demonstrated demyelination at 6 months, respectively (Table 1) . In some brains, the demyelination spread to the contralateral hemisphere and was not restricted to the site of injection (Figure 3f ). No gene expression was detected at 3 months as measured by staining for LacZ and immunofluorescence for interferon gamma (data not shown).
To study the effects of a higher dose of virus, two groups of animals were injected with 10 l of 2.0 × 10 12 viral particles/ml (AdIFN, n = 15; AdBGAL, n = 14). These mice were processed in a way similar to the groups of mice injected with the lower dose of adenovirus and their behavior and cognition compared with age-and sex-matched negative controls (n = 10). Mice injected with the higher dose of AdIFN performed as well as those implanted with AdBGAL, and both groups performed at least as well as negative controls in the open field, elevated plus maze, Morris water maze, rotarod, and cued and contextual fear tests (data not shown). Also, similar to the mice implanted by the lower dose of adenovirus, Gene Therapy all animals showed persistent inflammation characterized by astrocytosis and microglial infiltration at the site of injection (data not show). Two of five (40%) and one of five (20%) of the brains injected with high-dose AdBGAL and AdIFN showed demyelination at 3 months, respectively. Furthermore, seven of nine (78%) and seven of 10 (70%) demonstrated evidence of demyelination at 6 months, respectively (Table 1) .
Discussion
The data show that animals treated by adenovirusmediated gene transfer into the brain perform at least as well as wild-type (wt) mice in motor, behavioral and memory tests. Furthermore, gene transfer of interferon gamma into the brain does not elicit detectable cognitive deficits in animals. None the less, this study also demonstrates that adenoviral vectors, currently in use for clinical trials, elicit parenchymal inflammation and demyelination 6 months after treatment. In addition, the incidence of demyelination at 6 months rises sharply (40% to 70%) when the minimal effective dose is exceeded (Table 1) . There are concerns about the safety of adenoviral vectors and that inappropriate reactions may impede longawaited progress in gene therapy. 9, 10 Until such time when an 'ideal' vector is available, careful consideration ought to be given to the selection of the targeted patient population, the expected course of disease progression, potential side-effects, and the therapeutic window. A patient with malignant brain tumor may agree to an adverse reaction deemed unacceptable by an individual, Brains injected with 10 l of 0.8 × 10 12 viral particles/ml (L) or 2.0 × 10 12 viral particles/ml (H) of AdBGAL or AdIFN were sectioned at 3 (n = 5 each) and 6 months (n = 9 and 10 for AdBGAL and AdIFN, respectively) and examined for demyelination by staining with Luxol fast blue.
Figure 3 Adenovirus-mediated gene transfer elicits brain parenchymal inflammation and demyelination. Six months after injection with AdIFN (a-c) or AdBGAL (d-f), mice brains show intense astrocytosis (arrows, a and d), local infiltration by microglia at the site of injection (arrows, b and e) and demyelination (arrows, c and f) that may spread to the contralateral hemisphere (arrows, f). Astrocytes and microglia were identified by immunohistochemical reactivity with anti-GFAP and anti-lectin antibodies, and myelin was stained by Luxol fast blue. Original magnification is × 50.
whose expected survival is 20 years, if the therapy is associated with significant prolongation of life and tumor rejection. Our results uncover a narrow therapeutic window where the incidence of demyelination rises sharply soon after the effective therapeutic dose is achieved. This information is important for designing phase I clinical trials and may be relevant to defining the therapeutic window in humans. The relative and comparative vul-nerabilities of mouse and human brains to demyelination are not known. Knowledge pertaining to this issue is limited because agents that produce demyelination in rodent systems are not, in general, tested in humans. Because cognition in animals is different to that in humans, the question of whether adenovirus-mediated gene transfer into human brain elicits cognitive impairment may only be answered by prospective clinical trials. Nevertheless, absence of cognitive deficits in animal models is a necessary prerequisite for a study in humans.
Materials and methods
Animals and vectors C57/BL6 mice were bred at UT Southwestern Medical Center at Dallas, Texas, USA. Animal care was in accordance with institutional guidelines. The generation of the adenoviral vectors AdIFN and AdBGAL has been described elsewhere. 4 The titers of AdIFN and AdBGAL of viral particles/plaque forming units ratios are 43 and 81, respectively. Mice were anesthetized and injected intracerebrally as described previously. 4 Briefly, the viral vectors were injected 3.5 mm into the brain, 1 mm anterior and 2 mm to the right of the bregma.
Tissue staining Antibodies used are against mouse interferon gamma (ATCC, Manassas, VA, USA), tomato lectin (Sigma Chemical Company, St Louis, MO, USA), anti-GFAP (Dako Corporation, Carpenteria, CA, USA). Biotinylation reactions were performed following the manufacturer's specifications (Vector, Burlingame, CA, USA). Luxol fast blue, immunofluorescence and immunohistochemistry were performed as described previously. 4, 8 Brain sections were examined by two individuals and scored for the presence or absence of demyelination.
Open field
The open field test consists of the measurement of behaviour elicited by placing the animal in a novel open space from which escape was prevented by a surrounding wall. 11 This space was a box measuring 44 × 44 cm. Activity over 30 min was analyzed by the Auto-Track system (Columbus Instruments, Columbus, OH, USA). Consistent with previous reports, 12 the protocol and equipment used for this test have been validated to differentiate between normal and abnormal states in additional mice injected intraperitoneally with kainic acid (35 mg/kg; unpublished data).
Elevated plus maze
The maze consisted of two open arms and two enclosed (dark) arms, arranged such that the two pairs of identical arms were opposite to each other. The maze is elevated 25.5 inches above a white floor; each arm is 30 inches in length and 3.5 inches in width and the hub diameter is 12 inches. The closed arms are protected on both sides by a 7-inch-high plastic ridge. At the beginning of the 12-min test, mice were placed in the central hub. Two minutes later the doors leading to the arms opened automatically and the mice were allowed to explore freely. 13, 14 Time spent in each arm and the number of times a mouse enters the arms were recorded. The protocol and equipment used for this test have been validated in additional Gene Therapy isogenic 129SvEvTac and mixed strain mice by detecting strain-specific differences (unpublished data).
Morris water maze
The water maze was a circular pool, 2 feet high and 4 feet in diameter. The water temperature was maintained at 25°C (± 1°) and the water made opaque by adding water-soluble paint. Mice were trained over a 3-day period to swim from locations chosen in a random order (Figure 2a, stars) to a hidden platform placed in a fixed location in the center of quadrant 1. 15, 16 Each trial consisted of placing the animals in the water until the mouse reached the platform or for 60 s, whichever came first. Three trials were performed daily to a total of nine. After each trial, the mice remained on the platform for 20 s. One hour after the last swim, the mice were subjected to a probe trial in which they swam in the pool for 60 s after starting from a fixed position in quadrant 3. The pattern of swimming was analyzed by a computerized video tracking system (HVS Image, Cambridge, UK). Consistent with previous reports, 12 the protocol and equipment used for this test have been validated to differentiate between normal and abnormal states in additional mice injected intraperitoneally with kainic acid (35 mg/kg; unpublished data).
Rotarod
Mice were placed on the rod (Columbus Instruments) while it rotated at 5 r.p.m., and the rotation speed increased by 10 r.p.m./min. 17 The times that the animals were able to stay on the rod were recorded. Immediately after falling the animals received an electrical shock (1 s, 0.8 mA). Each mouse received three trials per day (waiting at least 30 min between trials) in each of 4 consecutive training days. The protocol and equipment used for this test have been validated to differentiate between normal and abnormal states in additional transgenic mice (unpublished data).
Cued and contextual memory
On the pre-training day, mice were allowed to explore for 10 min in a 29 × 22 × 13.5-cm chamber with a metal grid. [18] [19] [20] On the day of training, 3 min after the mouse was placed in the chamber, a conditioned stimulus of an 80 dB tone lasting for 30 s was presented and terminated by administration of the unconditioned (noxious) stimulus of a foot-shock (0.8 mA for 1 s). Two more tone-shock pairings were administered after 1-min intervals. Freezing was defined as a total lack of movement with the exception of respiration. Memory for either the contextshock or tone-shock association was assessed 24 h later by measuring the amount of freezing exhibited by the mice in the presence of the old context and in the presence of the tone in a second novel context consisting of a different box and a novel smell. For contextual memory, the mice were placed back in the training chamber and scored for freezing over 3 min, without applying conditioned stimulus. For cued memory, the animals were placed in a different chamber containing a novel smell and allowed to explore for 3 min without stimulus, followed by three 30 s tone presentations, each separated by 1 min. The protocol and equipment used for this test have been validated to differentiate between normal and abnormal states in additional knockout mice.
